Form 4: OS Therapies Director Karim Galzahr Receives Stock Options

OS Therapies Inc. Director Karim Galzahr was granted 140,000 stock options with an exercise price of $1.80, vesting in October 2026.

Summary

• Karim Galzahr, a Director of OS Therapies Inc. (OSTX), was granted 140,000 stock options.
• The options have an exercise price of $1.80 per share.
• The grant date for these options was October 21, 2025.
• The options are scheduled to vest in full on the one-year anniversary of the grant date, specifically October 21, 2026.
• Vesting is conditional on Karim Galzahr serving as a director of the issuer on the vesting date.
• The options have an expiration date of October 21, 2035.
• Following this transaction, Karim Galzahr beneficially owns 140,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a routine compensation event that aligns management interests with shareholders. It is generally viewed as a positive for corporate governance and incentivization, without indicating any immediate operational or financial performance issues.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term performance.
• Equity compensation is a standard practice for attracting and retaining qualified board members.

Negatives

• Potential for future dilution if the options are exercised, though this is a standard aspect of equity compensation plans.

Risks

• The options' value is dependent on the future market price of OS Therapies Inc. common stock exceeding the $1.80 exercise price.
• The options will only vest if Karim Galzahr remains a director until October 21, 2026, posing a retention risk for the company if he departs earlier.

Future Outlook

The filing indicates a future vesting event on October 21, 2026, contingent on the director's continued service. The options provide a long-term incentive structure extending to their expiration in 2035.

Industry Context

Granting stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as other growth-oriented sectors, to align leadership incentives with long-term shareholder value creation and to attract and retain talent.

Comparison to Industry Standards

• Equity compensation, particularly through stock options, is a widely accepted method for compensating non-employee directors across various industries, including biotech.
• The vesting schedule (one-year cliff) is a common approach to ensure director retention and commitment.
• The exercise price being set at the market price on the grant date (implied, as it's a grant) is standard for incentive stock options.
• Without specific peer company data, it is difficult to assess the size of the grant (140,000 options) relative to industry benchmarks for a director of a company of OS Therapies' size and stage.

Corporate Governance

Related Party Transactions

• The grant of stock options to Karim Galzahr, a director of OS Therapies Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors. This is a standard form of compensation and is typically disclosed and approved under corporate governance policies.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also improved alignment of director incentives with shareholder value creation.
• Director (Karim Galzahr): Receives significant equity compensation, providing a direct financial incentive tied to the company's stock performance and continued service.

Next Steps

• The options are scheduled to vest on October 21, 2026, provided the director remains in service.
• The director may choose to exercise the options at any time after vesting and before the expiration date of October 21, 2035, assuming the stock price is above the exercise price.

Key Dates

Keywords

OS Therapies Inc., OSTX, Karim Galzahr, stock options, Form 4, director compensation, equity grant, insider ownership, beneficial ownership